---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-013049"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2026-02-11T23:59:59+00:00"
generated_at: "2026-05-16T03:23:01.584039+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nuvectis Pharma reports FY2025 net loss $26.4M; cash $31.6M; NXP900 program advancing

## Summary
- Net loss $26.4M for FY2025 vs $19.0M in FY2024; includes $6.0M stock-based comp and $2.4M milestone license fees.
- Cash and equivalents $31.6M at Dec 31, 2025, up from $18.5M; funded by public offering and ATM facility.
- R&D expenses $18.2M (up from $12.9M), G&A $9.4M (up from $6.9M); finance income $1.1M.
- NXP900 Phase 1b monotherapy enrolling; combination with osimertinib (EGFR-mutated NSCLC) enrolling; lorlatinib combo pending.
- CEO expects current cash to fund operations through multiple Phase 1b milestones into H2 2027.

## SEC filing metadata
- accession: 0001104659-26-013049
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2026-02-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465926013049/0001104659-26-013049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465926013049/tm265090d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-013049
- JSON: https://secwatch.observer/filing/0001104659-26-013049.json
- Plain text: https://secwatch.observer/filing/0001104659-26-013049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.